UBS resumed coverage on British American Tobacco
$BTI
Medicinal Chemicals and Botanical Products
Health Care
UBS resumed coverage of British American Tobacco with a rating of Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/30/2025 | Buy | BofA Securities | |
| 1/27/2025 | Neutral → Buy | UBS | |
| 10/3/2024 | $33.00 | Overweight → Underweight | Morgan Stanley |
| 1/23/2024 | Neutral | UBS | |
| 11/1/2023 | $38.00 | Overweight | Morgan Stanley |
| 9/25/2023 | Buy | Citigroup | |
| 9/1/2023 | Buy → Hold | Argus | |
| 3/13/2023 | Overweight → Neutral | JP Morgan |